Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Jonathan Schwartz,

Press/Media

Period	12 Nov 2020 → 13 Nov 2020

Media coverage

20

Media coverage

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Business Wire
Country/Territory	United States
Date	13/11/20
URL	https://www.businesswire.com/news/home/20201113005176/en
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis; - ~$3.7 Million Clinical Grant to Fund U.S. Phase 1 Study of RP-L401 Gene Therapy
Media name/outlet	Business Wire
Country/Territory	United States
Date	13/11/20
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	StocksNewsFeed.com
Country/Territory	United States
Date	13/11/20
URL	https://stocksnewsfeed.com/businesswire/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical-trial-of-rp-l401-for-infantile-malignant-osteopetrosis/
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Yahoo! Finance
Country/Territory	United States
Date	13/11/20
URL	https://finance.yahoo.com/news/rocket-pharmaceuticals-receives-funding-california-120000548.html
Persons	Jonathan Schwartz,

Title	ROCKET PHARMACEUTICALS : Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	MarketScreener.com
Country/Territory	United States
Date	13/11/20
URL	https://www.marketscreener.com/quote/stock/ROCKET-PHARMACEUTICALS-I-40561561/news/Rocket-Pharmaceuticals-Receives-Funding-from-the-California-Institute-for-Regenerative-Medicine-fo-31774355/
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from th...
Media name/outlet	ADVFN Deutschland
Country/Territory	Germany
Date	13/11/20
URL	https://de.advfn.com/p.php?pid=nmona&article=83678816
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Crwe World
Country/Territory	United States
Date	13/11/20
URL	crweworld.com/article/news-provided-by-business-wire/1774627/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical-trial-of-rp-l401-for-infantile-malignant-osteopetrosis
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Drug Genius
Country/Territory	United States
Date	13/11/20
URL	https://druggenius.com/news/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical-trial-of-rp-l401-for-infantile-malignant-osteopetrosis/
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Jotup
Country/Territory	United States
Date	13/11/20
URL	https://jotup.co/node/1043694
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	BioSpace
Country/Territory	United States
Date	13/11/20
URL	https://www.biospace.com/article/releases/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical-trial-of-rp-l401-for-infantile-malignant-osteopetrosis-/?s=80
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	FirstWord Pharma
Country/Territory	United States
Date	13/11/20
URL	www.firstwordpharma.com/node/1774336
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Elk Valley Times
Country/Territory	United States
Date	13/11/20
URL	https://www.elkvalleytimes.com/news/business/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical/article_6bd699e1-38cd-5ff6-bcc0-dfabadaf409d.html
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Herald Chronicle
Country/Territory	United States
Date	13/11/20
URL	https://www.heraldchronicle.com/news/business/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical/article_0a479dba-aa1f-53c1-adce-b6281287d16d.html
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Tullahoma News
Country/Territory	United States
Date	13/11/20
URL	https://www.tullahomanews.com/news/business/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical/article_94a6bebc-ad34-5bd3-bfbd-159787e417a8.html
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Manchester Times
Country/Territory	United States
Date	13/11/20
URL	https://www.manchestertimes.com/news/business/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical/article_115e15fc-10de-5cbb-bf02-fe6742a92e99.html
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	OA Online
Country/Territory	United States
Date	13/11/20
URL	https://www.oaoa.com/news/business/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical/article_87991501-7b6a-53e1-848e-8de04b8123c0.html
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Newbridge Securities Corporation
Country/Territory	United States
Date	13/11/20
URL	https://www.newbridgesecurities.com/news/MARKCOMM/7659029220906200/
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Inc: Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis (Businesswire)
Media name/outlet	Avanza Bank AB
Country/Territory	Sweden
Date	13/11/20
URL	https://www.avanza.se/placera/pressmeddelanden/2020/11/13/rocket-pharmaceuticals-inc-rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical-trial-of-rp-l401-for-infantile-malignant-osteopetrosis.html
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
Media name/outlet	Digital Media Net
Country/Territory	United States
Date	13/11/20
URL	dmnnewswire.digitalmedianet.com/2020/11/13/rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical-trial-of-rp-l401-for-infantile-malignant-osteopetrosis/?utm_source=rss&utm_medium=rss&utm_campaign=rocket-pharmaceuticals-receives-funding-from-the-california-institute-for-regenerative-medicine-for-phase-1-clinical-trial-of-rp-l401-for-infantile-malignant-osteopetrosis
Persons	Jonathan Schwartz,

Title	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Ma
Media name/outlet	Acrofan
Date	12/11/20
URL	https://us.acrofan.com/detail.php?number=373374
Persons	Jonathan Schwartz,